Junhun Zhang - San Diego CA, US Anle Yang - San Diego CA, US Susan Elizabeth Kephart - San Diego CA, US Liming Dong - Shanghai, CN Chuangxing Guo - San Diego CA, US Yufeng Hong - San Diego CA, US Mary Catherine Johnson - San Diego CA, US Indrawan James McAlpine - San Diego CA, US Jayashree Tikhe - San Diego CA, US Haitao Li - Rockville MD, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61K 31/422 A61K 31/4162 C07D 261/06 C07D 231/54
US Classification:
514378, 514406, 548248, 5483605
Abstract:
Carbonylamino Pyrrolopyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
Junhu Zhang - San Diego CA, US Chuangxing Guo - San Diego CA, US Djamal Bouzida - San Diego CA, US Liming Dong - San Diego CA, US Haitao Li - San Diego CA, US Joseph Timothy Marakovits - Encinitas CA, US Anle Yang - San Diego CA, US Yufeng Hong - San Diego CA, US
Assignee:
Agouron Pharmaceuticals, Inc. - San Diego CA Pfizer Inc. - New York NY
International Classification:
C07D 491/00 A01N 43/90
US Classification:
544278, 5142601
Abstract:
Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
Junhu Zhang - San Diego CA, US Chuangxing Guo - San Diego CA, US Djamal Bouzida - San Diego CA, US Liming Dong - San Diego CA, US Haitao Li - San Diego CA, US Joseph Timothy Marakovits - Encinitas CA, US Anle Yang - San Diego CA, US Yufeng Hong - San Diego CA, US
Assignee:
Agouron Pharmaceuticals, Inc. - San Diego CA Pfizer Inc. - New York NY
International Classification:
C07D 491/00 A01N 43/90
US Classification:
544278, 5142601
Abstract:
Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
Klaus Dress - San Diego CA, US Qiyue Hu - Carlsbad CA, US Ted Johnson - San Clemente CA, US Michael Plewe - San Diego CA, US Steven Tanis - Carlsbad CA, US Hai Wang - San Diego CA, US Anle Yang - San Diego CA, US Chunfeng Yin - San Diego CA, US Junhu Zhang - San Diego CA, US
International Classification:
A61K031/4745 C07D471/02
US Classification:
514300000, 546113000
Abstract:
The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
Klaus Dress - San Diego CA, US Jon Kuehler - San Diego CA, US Michael Plewe - San Diego CA, US Anle Yang - San Diego CA, US Junhu Zhang - San Diego CA, US
International Classification:
A61K 31/44 C07D 471/02
US Classification:
514300000, 546113000
Abstract:
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions comprising compounds of formula (I), and their methods of use in treating HIV-infected mammals.